Measuring quality of life in patients with nodular lymphocyte-predominant Hodgkin lymphoma
Official title: A Pilot Study of Prospective Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Run by St. Jude Children's Research Hospital · NCT06098430 · Data updated 2026-11-12
This study is trying to understand how nodular lymphocyte-predominant Hodgkin lymphoma affects the quality of life for both kids and adults by collecting their feedback on symptoms and treatment experiences over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 8 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | St. Jude Children's Research Hospital Academic / other |
| Locations | 7 sites (Palo Alto, California and 6 other locations) |
| Status | Recruiting |
| Started | April 4, 2024 |
| Main results expected | February 2029 |
| Study ends | March 2030 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT06098430 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 8 years and older with a confirmed diagnosis of NLPHL who can provide consent and complete electronic surveys.
✕Probably not a fit
Patients younger than 8 years or those with concurrent diagnoses of other lymphomas may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study focuses on collecting and analyzing patient-reported outcomes (PROs) from both adult and pediatric patients diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). It aims to establish a data collection infrastructure for longitudinally tracking symptoms and treatment tolerability using validated PRO instruments. By examining how these outcomes change over time and are influenced by various patient and disease characteristics, the study seeks to enhance understanding of the patient experience in NLPHL. The findings could inform future treatment strategies and improve patient care.
Why it matters
Potential benefit: If successful, this study could lead to improved management of symptoms and better quality of life for patients with NLPHL.
How similar studies have gone: Other studies have successfully utilized patient-reported outcomes to improve understanding of treatment impacts, suggesting this approach is promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Age ≥ 8 years * Patient or their adult proxy must have verbal and written English language proficiency. * Pathologically confirmed diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL); patients with evidence of transformed lymphoma at diagnosis or subsequent development of transformed lymphoma after diagnosis are eligible. * Patients or their adult proxy must be able to provide consent. * Patients and/or adult proxy must be able to complete electronic quality of life surveys Exclusion Criteria * Age 7 years or less. * Patient or adult proxy does not have verbal and written English language proficiency. * Patients with histologic evidence of a composite lymphoma (NLPHL with a concurrent diagnosis of Hodgkin lymphoma, indolent non-Hodgkin lymphoma, or gray zone lymphoma) at diagnosis are not eligible. * Inability or unwillingness of research participant or legal guardian/representative to give consent.
Where it's running
-
Stanford University Medical Center
Palo Alto, California, United States Recruiting -
University of Colorado Hospital
Aurora, Colorado, United States Recruiting -
Dana-Farber Cancer Institute
Boston, Massachusetts, United States Recruiting -
Hackensack University Medical Center
Hackensack, New Jersey, United States Recruiting -
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting -
University of Rochester Medical Center
Rochester, New York, United States Recruiting
Show 1 more location
-
St. Jude Children's Research Hospital
Memphis, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Valerie Crabtree, PhD — St. Jude Children's Research Hospital
- Study coordinator: Valerie Crabtree, PhD
- Email: referralinfo@stjude.org
- Phone: 888-226-4343
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing two immunotherapy agents for treating a specific type of lymphoma
This study is testing whether a new immunotherapy called mosunetuzumab works better than the standard treatment rituximab for people with a specific type of lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.